Promising Potential of Arcus Biosciences’ ARC-20 Trial Drives Buy Rating

In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Arcus Biosciences (RCUS – Research Report), with a price target of $24.00.

Emily Bodnar’s rating is based on the promising potential of Arcus Biosciences’ ARC-20 trial, particularly the combination of casdatifan (cas) and cabozantinib (cabo). The upcoming presentation at ASCO is expected to provide initial data on the safety and efficacy of this combination, which could offer benefits over existing treatments. The safety profile of the combination has been consistent with expectations, and the anticipated objective response rate (ORR) of at least 40% would indicate a significant advantage over either agent alone.
Additionally, the ARC-20 trial includes multiple cohorts that will provide more comprehensive data throughout 2025, with mature results expected in 2026. This includes further insights into cas monotherapy and its combination with other agents. The strategic development of these trials and the potential for positive outcomes contribute to the Buy rating, as they suggest a strong future for Arcus Biosciences in the oncology space.

In another report released today, Barclays also maintained a Buy rating on the stock with a $14.00 price target.